Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.12 and traded as high as $2.95. Cortexyme shares last traded at $2.68, with a volume of 618,343 shares trading hands.
Cortexyme Trading Up 0.4%
The stock has a market cap of $81.11 million, a PE ratio of -0.91 and a beta of 1.40. The business’s 50-day moving average price is $2.92 and its 200-day moving average price is $2.12.
About Cortexyme
Cortexyme, Inc is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.
The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity.
See Also
- Five stocks we like better than Cortexyme
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
